Michael Osborn

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

Éric Bouffet, Valérie Larouche, Brittany Campbell et al. · Journal of Clinical Oncology · 2016 · 869 citations

Medicine, Molecular Genetics, Oncology +17

Comprehensive Analysis of Hypermutation in Human Cancer

Brittany Campbell, Nicholas Light, David Fabrizio et al. · Cell · 2017 · 796 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14

Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib

Deborah L. White, Phuong Dang, Jane R. Engler et al. · Journal of Clinical Oncology · 2010 · 183 citations

Medicine, Hematology, Pharmacology +11

Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency

Anirban Das, Sumedha Sudhaman, Daniel A. Morgenstern et al. · Nature Medicine · 2022 · 144 citations · Full text

Life Sciences, Immunology, Oncology +10

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

David T Yeung, Michael Osborn, Deborah L. White et al. · Blood · 2014 · 103 citations · Full text

Medicine, Molecular Biology, Molecular Pharmacology +5